Komori
Share Issuance and Disposal190AChordia Therapeutics Inc.Pharmaceuticals

Notice Concerning the Monthly Exercise Status of the 12th Stock Acquisition Rights (with Exercise Price Adjustment Clause)

During September 2026, 1,000 of the 12th Series of Stock Acquisition Rights were exercised, and 100,000 shares were delivered. The number of unexercised stock acquisition rights at month-end was 183,220.

Worth reading
38Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
100000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status report for the 12th Series of Stock Acquisition Rights with Exercise Price Adjustment Clause

発行・処分する株式数

Shares delivered during the month: 100,000 shares (100,000 new shares, 0 transferred treasury shares)

Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥60.3, ¥61.2, ¥62.1 and ¥63.0. Details of the adjustment clause are not disclosed in this document.
Number of Stock Acquisition Rights
Number exercised during the month: 1,000 (0.54% of the total issued); number unexercised at the beginning of the reporting month: 184,220; number unexercised at month-end: 183,220
Procedures under the Corporate Code of Conduct
Describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
9 September 2026: Issuance of the 12th Series of Stock Acquisition Rights (see the materials released on 24 August 2026 for details)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status report for the 12th Series of Stock Acquisition Rights with Exercise Price Adjustment Clause
Number of shares to be issued or disposed ofShares delivered during the month: 100,000 shares (100,000 new shares, 0 transferred treasury shares)
Total number of issued shares77,258,400 shares (as of the end of the month preceding the reporting month; treasury shares: 0) → Not disclosed
Exercise priceExercise prices during the month: ¥60.3, ¥61.2, ¥62.1 and ¥63.0. Details of the adjustment clause are not disclosed in this document.
Number of Stock Acquisition RightsNumber exercised during the month: 1,000 (0.54% of the total issued); number unexercised at the beginning of the reporting month: 184,220; number unexercised at month-end: 183,220
Procedures under the Corporate Code of ConductDescribes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing9 September 2026: Issuance of the 12th Series of Stock Acquisition Rights (see the materials released on 24 August 2026 for details)
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status and compliance with exercise restrictions.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of the 12th Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chordia Therapeutics Inc. (190A) timely disclosure | Komori